Developing Treatments to Combat Resistant Infectious Diseases|Alan Dunton,MD,Oragenics Inc 00:10:00
Dr. Dunton has served as a Director of Oragenics, Inc. since April 2010. He is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. In addition to Oragenics, he is currently a Director of the public biotechnology company, Palatin, Inc. (AMEX: PTN), CorMedix (NASDAQ: CRMD) and Recce Pharmaceuticals (ASX: RCE). Dr. Dunton previously served as a Director of Sancilio and Company, MediciNova, Regeneus, and Targacept, Inc. Dr. Dunton is also a member of the Board of Director of CorMedix, Inc. (CRMD), a publicly traded biotechnology company in Berkeley Heights, New Jersey since March 2019. Dr. Dunton has held significant senior positions in major pharmaceutical companies.